Occurrence, Predictors, and Outcomes of Post‐Percutaneous Coronary Intervention Thrombocytopenia in an Unselected Population

Abstract

Post-PCI thrombocytopenia occurred in 3.1% of patients in an unselected real-world population and carried a significant detrimental impact on prognosis. Failed PCI was the strongest correlate identified.

Drug-Eluting Stents in Patients with Chronic Kidney Disease: A Prospective Registry Study

“…As described previously [10], [11], demographic, clinical, angiographic, laboratory values and in-hospital outcomes are collected by dedicated specially trained nursing personnel, in a standardized fashion in accordance with American College of Cardiology National Cardiovascular Data Registry (ACC-NCDR) definitions [12]. Longitudinal follow-up information is obtained annually using multiple concurrent approaches including patient follow-up visits, surveillance of medical records, contact with primary care providers, telephone contacts with registry participants or next-of-kin, and linkage with the Social Security Administration Death Master File.…”

The impact of acquired thrombocytopenia on long‐term outcomes of patients undergoing elective percutaneous coronary intervention: An analysis of 8,271 consecutive patients

“…Current guidelines for patients with moderate‐ or high‐risk acute coronary syndromes (ACS) recommend early invasive management with concomitant antithrombotic therapy, including antithrombotic medications, coronary artery bypass grafting surgery (CABG), and percutaneous coronary intervention (PCI) . However, these therapies may cause acquired thrombocytopenia and have been strongly associated with an increased risk of hemorrhagic and ischemic complications, as well as early mortality . To date, few data exist regarding the impact of acquired thrombocytopenia on the long‐term outcomes of patients who underwent elective PCI for stable angina or low‐risk ACS.…”

“…coronary artery bypass grafting surgery (CABG), and percutaneous coronary intervention (PCI) [1][2][3]. However, these therapies may cause acquired thrombocytopenia and have been strongly associated with an increased risk of hemorrhagic and ischemic complications, as well as early mortality [4][5][6][7][8]. To date, few data exist regarding the impact of acquired thrombocytopenia on the long-term outcomes of patients who underwent elective PCI for stable angina or low-risk ACS.…”

Guthrie Health Off‐Label Stent (GHOST) Registry

“…Several analyses from the Guthrie Health Off‐Label StenT Registry (GHOST), an ongoing prospective observational single‐center database, have been published in the Journal of Interventional Cardiology 1–4 and other journals 5–9 . Our outcomes analyses have focused on the assessment of key clinical end‐points in patients undergoing percutaneous coronary interventions (PCI).…”

“…To quantitate the degree of overestimation in prior analyses, we compared the MACE follow‐up duration by the old and new methods in 4,336 index PCI procedures. Some of our prior analyses were restricted to patients who underwent PCI between 2001–2003, 3, 7, 9 2001–2005, 4 2001–2006, 8 and 2001–2007 2, 5 . Therefore, we compared the old and new methods in subsets of patients who underwent PCI at different time periods.…”